Benefit, Harm, and Cost-effectiveness Associated With Magnetic Resonance Imaging Before Biopsy in Age-based and Risk-stratified Screening for Prostate Cancer

MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis

(2020) Michael Ahdoot et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Four-Kallikrein Panel Is Effective in Identifying Aggressive Prostate Cancer in a Multiethnic Population

(2020) Burcu F. Darst et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Polygenic risk-tailored screening for prostate cancer: A benefit–harm and cost-effectiveness modelling study

(2019) Tom Callender et al.   PLOS MEDICINE

Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS)

(2018) Rita Faria et al.   EUROPEAN UROLOGY

Screening for Prostate Cancer

(2018) et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis

(2018) Veeru Kasivisvanathan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts

(2018) Tyler M Seibert et al.   BMJ-British Medical Journal

Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts

(2018) Tyler M Seibert et al.   BMJ-British Medical Journal

Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer

(2018) Nora Pashayan et al.   JAMA Oncology

Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis

(2018) Dragan Ilic et al.   BMJ-British Medical Journal

Germline variation at 8q24 and prostate cancer risk in men of European ancestry

(2018) Marco Matejcic et al.   Nature Communications

Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study

(2017) Hashim U Ahmed et al.   LANCET

PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2

(2016) Jeffrey C. Weinreb et al.   EUROPEAN UROLOGY

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer

(2016) Freddie C. Hamdy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis

(2015) Nora Pashayan et al.   GENETICS IN MEDICINE

Estimating the cost of caring for people with cancer at the end of life: A modelling study

(2015) Jeff Round et al.   PALLIATIVE MEDICINE

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up

(2014) Fritz H Schröder et al.   LANCET

Quality-of-Life Effects of Prostate-Specific Antigen Screening

(2012) Eveline A.M. Heijnsdijk et al.   NEW ENGLAND JOURNAL OF MEDICINE

Using Health State Utility Values from the General Population to Approximate Baselines in Decision Analytic Models when Condition-Specific Data are Not Available

(2011) Roberta Ara et al.   VALUE IN HEALTH

Mean sojourn time, overdiagnosis and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening

(2009) N Pashayan et al.   BRITISH JOURNAL OF CANCER